We are the “D” in ADCs and PDCs.
A universal, light-activatable intracellular payload that adds an independent spatial control layer to molecular tumor targeting.
Our mission: make cancer a treatable disease — eliminating cancer cell by cell.
GenLumina combines a high-upside preclinical therapeutics platform with a concrete route to strategic validation: a proposed Roche/Genentech feasibility collaboration using Roche-selected targeting biology.
A direct match with Roche Venture Fund's investment profile.
RVF seeks innovative private life-science companies, focuses on Series A, prefers preclinical therapeutics and can invest alongside Roche or Genentech collaborations.
Preclinical therapeutics
GenLumina is at the stage RVF explicitly prefers for therapeutic investments.
Series A focus
A staged €5M financing sits within RVF's typical CHF 3–10M first-round investment range.
Innovation with high upside
A universal controllable payload adds a new spatial control layer to targeted oncology.
Investment + collaboration
The proposed Roche/Genentech feasibility work creates a parallel path to strategic validation.
Two layers of precision. One controllable payload.
Molecular targeting determines where the payload goes. Light adds an independent spatial switch that controls where cytotoxic activity is activated.
Molecular targeting
Antibody or peptide directs the payload to tumor cells.
Intracellular delivery
Payload enters and localises within target cells.
Spatial activation
Local light activates the intracellular payload.
Selective killing
Activated payload drives tumor-cell cytotoxicity.
The payload remains the field's core limitation.
Targeting has advanced. Yet systemic toxicity and a narrow therapeutic window continue to constrain ADCs and PDCs. GenLumina adds a second, independent layer of selectivity: local light activation.
- In-vitro proof-of-concept in targeted and conjugated approaches
- Activity shown in breast and colorectal cancer models
- In-vivo proof-of-concept and partner-specific conjugate validation
- Selectivity and therapeutic-window data across additional ligands
Built to partner broadly.
Modular conjugation to antibodies, peptides and other targeting ligands — designed to work with existing biology and image-guided workflows.
€5M to CTA/IND-ready.
One financing objective: advance a jointly selected conjugate through in-vivo validation and the studies needed to prepare a clinical trial application in Europe (CTA) or the United States (IND).
Strategic lead investor and co-investors.
In-vivo proof-of-concept and CTA/IND-enabling work.
One validated conjugate of choice.
Invest in the controllable payload layer for targeted oncology.
We welcome Roche Venture Fund as a strategic investor in a staged €5M financing and invite a parallel scientific collaboration with Roche/Genentech.